PhD Candidate
University at Buffalo
Kirk Hofman is currently a Ph.D. candidate at the University of Buffalo, School of Pharmacy and Pharmaceutical Sciences. His research is focused on gene and cell therapy immunogenicity assessment with an emphasis on Adeno-associated virus (AAV) immunogenicity as well as Chimeric Antigen Receptor T cell (CAR-T) Immunogenicty. He is currently working as a COOP-Intern at Bristol-Myers Squibb, assessing the ability of ex-vivo whole blood culture systems to assess cellular immune response to CAR-T cell therapies. He has been a student researcher in Dr. Balu-Iyer's lab at the University of Buffalo since 2015 and completed his MS in Pharmaceutical Sciences in 2018 titled "Impact of Fc Fusion on FVIII Stability, Immunogenicity, and Subcutaneous Pharmacokinetics".
Disclosure information not submitted.
Wednesday, April 26, 2023
2:00 PM – 2:15 PM ET